News
RDY
73.35
+1.44%
1.04
Dr. Reddy’s Bags Exclusive Vaccine Distribution Deal
TipRanks · 1d ago
Dr. Reddy's Laboratories Reaches Analyst Target Price
NASDAQ · 4d ago
Weekly Report: what happened at RDY last week (0318-0322)?
Weekly Report · 4d ago
Dr. Reddy’s Launches Novel Shock Treatment in India
TipRanks · 03/22 12:28
Dr. Reddy’s Upcoming Board Meeting & Trading Window Closure
TipRanks · 03/22 12:27
Dr. Reddy’s Debuts Cancer Biosimilar in the UK
TipRanks · 03/19 11:28
Weekly Report: what happened at RDY last week (0311-0315)?
Weekly Report · 03/18 09:05
Dr Reddys Labs: Report of foreign issuer
Press release · 03/15 14:20
Weekly Report: what happened at RDY last week (0304-0308)?
Weekly Report · 03/11 09:05
Weekly Report: what happened at RDY last week (0226-0301)?
Weekly Report · 03/04 09:05
Zydus aims to launch first new drug in US by early 2026
Zydus aims to launch first drug in US by early 2026. The company received a fast-track designation from the U.S. FDA for its Saroglitazar drug. Zydus is looking to tap into the multi-billion dollar market for treating a type of liver disease.
Reuters · 02/27 14:48
Weekly Report: what happened at RDY last week (0219-0223)?
Weekly Report · 02/26 09:06
What to Watch in the Week Ahead and Monday, February 26
Domino's Pizza is expected to post a rise in its fourth-quarter sales. The Commerce Department is set to release economic data for January. A busy week ahead for Federal Reserve officials with many scheduled to participate in different events. The Day Ahead includes the day's major stories and events.
Reuters · 02/23 19:30
Novo to face Wegovy competition in India as local versions loom: Reuters
Several Indian drugmakers already working on their version of Novo Nordisk's Wegovy. The Danish drugmaker has yet to launch WegovY in India. Novo to face competition in India as local versions loom: Reuters. The company's WeGovy patents are expected to expire in 2026 in China and 2032 in the U.S.
Seeking Alpha · 02/22 15:21
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Novo Nordisk A/S plans to introduce Wegovy in India by 2026. Indian drugmakers are aggressively pursuing the development of generic versions of the weight-loss drug. The patents for WegovY are set to expire in various regions between 2026 and 2032.
Benzinga · 02/22 15:01
Weekly Report: what happened at RDY last week (0212-0216)?
Weekly Report · 02/19 09:06
BUZZ-Novartis India hits 24-year high on report of interest from Dr Reddy's
Shares of Novartis India NOIN.BO rise as much as 10.9% to 1,148 rupees, highest since Feb. 7, 2000. Dr Reddy's REDY.NS reported to be interested in buying a stake in the company. Noin shares have risen 15% so far in February.
Reuters · 02/19 06:39
BRIEF-Dr Reddy’S In Race To Acquire Novartis AG’s Stake In Novartis India - CNBC TV-18
Dr Reddy's In Race To Acquire Novartis AG’s Stake InNovartis India - CNBC TV-18. DR REDDY’S MAY OFFER CONTROLLING PREMIUM FOR NOVARTIS AG”s STAKE IN NOVartis INDIA.
Reuters · 02/17 06:15
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's. The company has expanded its pipeline and is in a strong position for upcoming clinical success and potential regulatory approval. Coya has been a standout in clinical trials for ALS and Alzheimer's disease.
Seeking Alpha · 02/13 13:25
Weekly Report: what happened at RDY last week (0205-0209)?
Weekly Report · 02/12 09:06
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).